Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.

摘要: Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) treatment everolimus–exemestane (E/E) is an established effective hormone receptor-positive/HER2-negative mBC patients. The effect E/E on was prospectively investigated. from 50 pre-treated receiving were analyzed using the CellSearch (CS) platform triple immunofluorescence (IF) staining for cytokeratin, M30 Ki67 expression to assess their proliferative apoptotic status. (by CS) detected 64% before administration resulted decreased prevalence [(n = 18; 36%, p = 0.004) (n = 7; 19.4%, p = 0.019) post-1st post-3rd cycle, respectively] whereas it significantly increased at disease progression (PD: 61%) compared cycle (p = 0.049 p = 0.021, respectively). Ki67-positive 60%, 17% 50% treatment, post-1st, PD, respectively, while opposite observed M30-positive (0% baseline, 10% after 1st 3rd 0% PD). detection even ≥ 1 CTC/5 ml one associated PFS (3.3 vs 9.0 months, p = 0.025) even ≥ 2 PD OS (32.4 19.5 months; p = 0.009). combination elimination proliferating this favorable clinical outcome.